Chronic myelomonocytic leukemia: from biology to therapy.
暂无分享,去创建一个
A. Baruchel | E. Wattel | P. Fenaux | C. Chomienne | N. Cambier | M. Schlageter | M. Menot | André Baruchel | P. Fenaux | Menot Ml | N. Cambier | A. Baruchel | M. H. Schlageter | E. Wattel | P. Fenaux | C. Chomienne | Christine Chomienne | Nathalie Cambier
[1] G. Mufti,et al. Possible co-existence of RAS activation and monosomy 7 in the leukaemic transformation of myelodysplastic syndromes. , 1995, Leukemia research.
[2] C. Preudhomme,et al. Prognostic value of c-mpl expression in myelodysplastic syndromes. , 1995, Leukemia.
[3] U. Germing,et al. Risk assessment in primary myelodysplastic syndromes: validation of the Düsseldorf score. , 1994, Leukemia.
[4] P. Fenaux,et al. Modulation of IL-8, IL-1 beta, and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukemia. , 1994, Leukemia.
[5] B. Quesnel,et al. Inactivation of the retinoblastoma gene appears to be very uncommon in myelodysplastic syndromes , 1994, British journal of haematology.
[6] C. Denny,et al. Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about , 1994, Cell.
[7] P. O'Connell,et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. , 1994, The New England journal of medicine.
[8] N. Iscove,et al. Overexpression of PDGF-B in murine hematopoietic cells induces a lethal myeloproliferative syndrome in vivo. , 1994, Oncogene.
[9] N. Gattermann,et al. All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study. , 1993, Blood.
[10] J. Guénet,et al. Characterization of the murine Mpl proto-oncogene, a member of the hematopoietic cytokine receptor family: molecular cloning, chromosomal location and evidence for a function in cell growth. , 1993, Oncogene.
[11] E. Estey,et al. All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] F. McCormick,et al. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. , 1993, Blood.
[13] P. Sonneveld,et al. High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype. , 1993, Leukemia.
[14] G. Mufti,et al. Myelodysplastic syndromes: from morphology to molecular biology. Part II. The molecular genetics of myelodysplasia. , 1993, International journal of hematology.
[15] J. Rowley,et al. Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion , 1993 .
[16] T. Naoe,et al. Treatment of myelodysplastic syndromes with all-trans retinoic acid. Leukemia Study Group of the Ministry of Health and Welfare. , 1993, Blood.
[17] P. Martiat,et al. Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome? , 1993, Leukemia & lymphoma.
[18] W. Fibbe,et al. t(5;12)(q31;p12). A clinical entity with features of both myeloid leukemia and chronic myelomonocytic leukemia. , 1993, Cancer genetics and cytogenetics.
[19] I. Pannacciulli,et al. MYELODYSPLASTIC SYNDROME ASSOCIATED WITH INCREASED BONE MARROW FIBROSIS AND TRANSLOCATION (5;12)(q33:p12·3) , 1992, British journal of haematology.
[20] R. Warrell,et al. The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia , 1992, Annals of Internal Medicine.
[21] S. Pileri,et al. Overexpression of multidrug resistance‐associated p170‐glycoprotein in acute non‐lymphocytic leukemia , 1992, European journal of haematology.
[22] M. Mangi,et al. Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies. , 1992, Blood.
[23] R. Berger,et al. Mutations in the p53 gene in myelodysplastic syndromes. , 1991, Oncogene.
[24] P. Shaw,et al. Occurrence of Ki-ras and p53 mutations in primary colorectal tumors. , 1991, Oncogene.
[25] R. Berger,et al. P53 gene mutations in acute myeloid leukemia with 17p monosomy. , 1991, Blood.
[26] M. Minden,et al. Mutation of the p53 gene in human acute myelogenous leukemia. , 1991, Blood.
[27] P. Morel,et al. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy , 1991, British journal of haematology.
[28] Y. Neuman,et al. Atypical chronic myelomonocytic leukemia with eosinophilia and translocation (5;12). A new association. , 1991, Cancer genetics and cytogenetics.
[29] P. O’Connell,et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21 , 1990, Cell.
[30] P. Fenaux,et al. All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. , 1990, Blood.
[31] C. T. Davis,et al. Minimal subenhancer requirements for high-level polyomavirus DNA replication: a cell-specific synergy of PEA3 and PEA1 sites , 1990, Molecular and cellular biology.
[32] C. March,et al. A new cytokine receptor superfamily. , 1990, Trends in biochemical sciences.
[33] A. Kitzis,et al. Ras activation in myelodysplastic syndromes: clinical and molecular study of the chronic phase of the disease , 1990, British journal of haematology.
[34] J. Goasguen,et al. Prognostic factors of myelodysplastic syndromes--a simplified 3-D scoring system. , 1990, Leukemia research.
[35] M. Lavin,et al. Cell death by apoptosis in acute leukaemia , 1989, The Journal of pathology.
[36] Yunis Jj,et al. Mechanisms of ras mutation in myelodysplastic syndrome. , 1989 .
[37] E. Montserrat,et al. Acute transformation of chronic myelomonocytic leukaemia: a multivariate study of predictive factors , 1989, European journal of haematology.
[38] N. Heerema,et al. KRAS2 oncogene overexpression in myelodysplastic syndrome with translocation 5;12. , 1988, Cancer genetics and cytogenetics.
[39] F. McCormick,et al. RAS mutations in myelodysplasia detected by amplification, oligonucleotide hybridization, and transformation. , 1988, Leukemia.
[40] G. Mufti,et al. Mutation of Ki-ras and N-ras oncogenes in myelodysplastic syndromes. , 1988, Blood.
[41] F. Grant,et al. Cloning and expression of a cDNA coding for the human platelet-derived growth factor receptor: evidence for more than one receptor class. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[42] R. Saiki,et al. Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[43] D. Heitjan,et al. Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders. , 1988, Blood.
[44] C. Bartram,et al. RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[45] W. Wilmanns,et al. Mechanisms and prognostic value of cell kinetics in the myelodysplastic syndromes , 1987, British journal of haematology.
[46] V. Broudy,et al. Cytogenetic evidence for involvement of B lymphocytes in acquired idiopathic sideroblastic anemias. , 1987, Blood.
[47] Prognostic factors and survival in chronic myelomonocytic leukaemia (CMML). , 1987, British Journal of Cancer.
[48] P. Fenaux,et al. Chronic and subacute myelomonocytic leukaemia in the adult: a report of 60 cases with special reference to prognostic factors , 1987, British journal of haematology.
[49] J. Hermans,et al. Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases , 1987, British journal of haematology.
[50] R. Simon,et al. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] Galton Da,et al. Myelodysplastic syndromes: natural history and features of prognostic importance. , 1986, Clinics in haematology.
[52] J. Griffin,et al. Autocrine secretion of GM-CSF in acute myeloblastic leukemia. , 1986, Blood.
[53] A. Ullrich,et al. Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors , 1986, Nature.
[54] G. Mufti,et al. Immunological abnormalities in myelodysplastic syndromes I. SERUM IMMUNOGLOBULINS AND AUTOANTIBODIES , 1986, British journal of haematology.
[55] Chronic myelomonocytic leukemia: Clinical features, cytogenetics, and prognosis in 30 consecutive cases , 1985, Hematological oncology.
[56] V. Rotter,et al. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation , 1984, Nature.
[57] P. Fialkow,et al. Evidence for a multistep pathogenesis of a myelodysplastic syndrome. , 1984, Blood.
[58] P. Seeburg,et al. Tripartite structure of the avian erythroblastosis virus E26 transforming gene , 1983, Nature.
[59] H. Gralnick,et al. Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.
[60] R L Juliano,et al. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.